Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth

Albany, NY -- (SBWire) -- 12/12/2013 --Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth

The pharma report - “Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth”. There are currently three monoclonal Antibody (mAb) treatments approved for metastatic colorectal cancer with the purpose of extending the patient’s lifespan; Avastin, Erbitux and Vectibix. The current market leader is Avastin, which generated revenues of $6.2 billion in 2012 across a number of oncology indications. While compelling late-stage candidates are absent from the current pipeline, the anticipated rise in total prevalence of colorectal cancer in the top eight markets may inspire further investment. Pricing patterns for mAbs are highly favorable in the US, the largest market for colorectal cancer, and patent expirations are not expected to have a substantial effect on any of the featured markets. As a result of this, GBI Research believes the global market has the potential to grow to a value of $5.5 billion by 2019.

To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis-details/monoclonal-antibodies-market-in-colorectal-cancer-to-2019-favorable-pricing-policy-in-the-us-and-rising-prevalence-in-europe-and-japan-ensures-market-growth

Scope

- A brief introduction to colorectal cancer, including the disease’s pathogenesis, etiology, diagnosis and treatment algorithms.
- In-depth analysis of the three mAbs marketed for colorectal cancer, including analysis of their safety, efficacy, treatment patterns and strengths/weaknesses. Including a heat map comparing the drugs in terms of safety and efficacy.
- A comprehensive review of the pipeline for colorectal cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types, program types, mechanisms of action and molecular targets.
- Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate for each molecule type, in addition to an in-depth analysis of clinical trial primary endpoints.
- Multi-scenario forecast data of the market to 2019, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets.
- Discussion of the drivers and barriers for market growth.
- In-depth analysis of all licensing and co-development deals that have occurred in the colorectal cancer market since 2006.

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/180935

Reasons to Buy

- Understand the role of mAbs in the treatment of colorectal cancer and their relation to chemotherapies and targeted small molecule therapies.
- Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent.
- Observe the trends in clinical trial duration and size amongst clinical phases and molecule types. Use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for colorectal cancer therapeutics.
- Observe the shift in clinical trial endpoints throughout clinical phases of development, and use this data to potentially influence any future developmental programs.
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the colorectal cancer mAbs market.

Table of Contents

1 Table of Contents 1
1.1 List of Tables 3
1.2 List of Figures 4

2 Executive Summary 5
2.1 Monoclonal Antibodies Favored in the Market for Metastatic Colorectal Cancer 5
2.2 Strong Pipeline to Drive Growth to 2019 5

3 Monoclonal Antibodies in Colorectal Cancer Market to 2019 – Introduction 7
3.1 Symptoms 7
3.2 Etiology 7
3.3 Epidemiology 8
3.4 Pathophysiology 9
3.5 Diagnosis 9
3.6 Prognosis and Disease Staging 10
3.7 Treatment Options 11
3.7.1 Chemotherapy 11
3.7.2 Targeted Therapies 12
3.7.3 Resistance to Pharmacological Therapies 13
3.7.4 Treatment Guidelines 13
3.8 GBI Research Report Guidance 15

4 Monoclonal Antibodies in Colorectal Cancer Market to 2019 – Marketed Products 16
4.1 Avastin (Bevacizumab) – Hoffman La Roche 16
4.2 Erbitux (Cetuximab) – Bristol-Myers Squibb, Eli Lilly, and Merck KGaA 18
4.3 Vectibix (Panitumumab) – Amgen and Takeda 19
4.4 Heat Map for Marketed Products 20
4.5 Conclusion 22

5 Monoclonal Antibodies in Colorectal Cancer Market to 2019 – Developmental Pipeline 23
5.1 Overall Pipeline 23
5.2 Molecular Targets and Mechanisms of Action 25
5.3 Clinical Trials 26
5.3.1 Failure Rate 26
5.3.2 Clinical Trial Size 27
5.3.3 Duration 30
5.3.4 Primary Endpoints 31
5.4 Conclusion 33
5.5 Key Late-Stage Pipeline Products 33
5.5.1 IMC-1121B (Ramucirumab) – Eli Lilly and Company 33
5.5.2 Xilonix – XBiotech 34
5.5.3 MetMAb (Onartuzumab) – Hoffmann-La Roche 34
5.5.4 Anti-DR5 MoAb (Tigatuzumab) – Daiichi Sankyo 34
5.5.5 MK0646 (Dalotuzumab) – Merck 35
5.5.6 AMG-655 (Conatumumab) – Amgen 36
5.6 Conclusion 36

To Buy The Copy of This Report Visit: http://www.marketresearchreports.biz/analysis/180935

6 Monoclonal Antibodies in Colorectal Cancer Market to 2019- Market Forecast to 2019 36
6.1 Global 38
6.1.1 Treatment Usage Patterns 38
6.1.2 Market Size 39
6.2 North America 40
6.2.1 US 40
6.2.2 Canada 42
6.3 Europe 43
6.3.1 Treatment Usage Patterns 43
6.3.2 Annual Cost of Therapy 44
6.3.3 Market Size 46
6.4 Japan 47
6.4.1 Treatment Usage Patterns 47
6.4.2 Market Size 48
6.5 Drivers and Barriers 48
6.5.1 Drivers 48
6.5.2 Barriers 49

7 Monoclonal Antibodies in Colorectal Cancer Market to 2019- Deals and Strategic Consolidations 51
7.1 R&D Licensing Agreements 51
7.1.1 Key Licensing Deals 54
7.2 Co-Development Agreements 56
7.2.1 Key Co-Development Agreements 57

8 Monoclonal Antibodies in Colorectal Cancer Market to 2019- Appendix 58

Latest Reports:

Hemoglobin A1c Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019: http://www.marketresearchreports.biz/analysis-details/hemoglobin-a1c-testing-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019

Blood glucose testing at regular intervals is very crucial for diabetic patients, in order to keep a track of fluctuating glucose levels in the blood. The crucial aim of diabetes treatment is to ensure normal levels of blood glucose. Hemoglobin A1c (Hb A1c) is a lab test that gives an idea about average levels of blood sugar for a period of around three months. The test results give an idea about the efficacy of diabetes treatment plans. It provides insights on the following parameters:

- Success of the designed diabetes treatment plan.
- Accuracy of test results

The mechanism of test includes linking of hemoglobin to glucose molecules in red blood cells. With increasing levels of glucose in red blood cells, there is a high possibility of hemoglobin molecules being glycated or linked with glucose molecules. It is recommended to perform the test atleast twice in a year. A1c levels are reported in terms of percentages. Presently, American Association of Clinical Endocrinologists recommends around 6.5% A1c to be normal concentration and American Diabetes Association recommends less than 7.0% A1c in the blood cells.

The market for hemoglobin A1c testing is witnessing a consistent growth trend majorly due to increasing incidence of diabetes mellitus across the globe. According to the data enumerated by WHO, there are around 347 million diabetic patients worldwide and diabetes will be seventh leading cause of death by 2030. Currently, with the approval of U.S. FDA for these tests or assays for diagnosing diabetes by healthcare professionals, the demand and acceptance of HbA1c tests will further increase.

Some of the major factors fueling the market growth are increased demand for continuous monitoring and management of diabetes worldwide and focus on the development of technologically sound and portable monitoring devices. In addition, higher efficiency of these devices followed by the ease of use, high reliability and quick results further augment the market growth. Negligence for testing in low income nations and lack of appropriate awareness about these tests might hamper the market growth. Some of the major market players competing in this market are Abbott Laboratories, Bayer Healthcare Diagnostics, Bio-Rad Laboratories, Inc., and Siemens AG.

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/toc/175727

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

- North America
- Asia Pacific
- Europe
- Rest of the World

This report provides comprehensive analysis of

- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Central Nervous System (CNS) Biomarkers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019: http://www.marketresearchreports.biz/analysis-details/central-nervous-system-cns-biomarkers-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019

Biomarkers are used to indicate the biological state of a process, pathogenic process or therapeutic action. Biomarkers facilitate understanding the development of a chronic disease, relationship between exposure to environmental chemicals and identification of subgroups of people who are relatively at high risk of developing disease. Continued development in related technologies such as genomics, proteomics and imaging system has accelerated the development of biomarkers. With the complexity of Central Nervous System (CNS), it is considered that biomarkers will play a vital role in identifying several neurodegenerative diseases at early stage, provide more accurate diagnosis and better treatment.

The global market for Central Nervous System biomarkers has been growing rapidly over the past two decades and is expected to continue further under the influence of increased governmental support, rapidly increasing aging population and advancements in supporting technologies such as genomics, proteomics and imaging technologies. The world is witnessing a rapid growth in aging population leading to high prevalence of many CNS disorders such as Parkinson’s, multiple sclerosis and Alzheimer’s disease. The Aging Research Center, Karoliska Institute, Sweden suggests that approximately 24 million are affected with Alzheimer’s disease worldwide.

These diseases incur significant burden on society, to overcome these burdens governments are supporting private and public laboratories by funding to continue their development process. United States government has proposed to spend USD 140.8 billion in the fiscal 2013 to support research and development program across the country. Geographically, North America represents the largest market as healthcare infrastructure ismore advanced as compared to other regions around the globe and it also has a large population base suffering from CNS diseases. The emerging markets including India, china, Brazil and Mexico are poised to show substantial growth due to continuously improving healthcare facilities in these nations.

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/toc/175728

Some of the prominent players engaged in the development and marketing of biomarkers are AbaStar MDX, Apitope International, ExonHit Therapeutics, Metabolon Inc., Myriad RBM, OPKO Health, Thermo Fisher Scientific and Osta Biotechnologies.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

- North America
- Asia Pacific
- Europe
- Rest of the World

This report provides comprehensive analysis of

- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

About MarketResearchReports
MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
Blog: http://mrrfocuseconomics.blogspot.com/